Cirio advises Abliva on private placement of 26.7 million shares

Cirio has advised Abliva AB (publ), listed on Nasdaq Stockholm, in connection with its private placement of 26.7 million shares directed towards the Nordic life science investor Hadean Ventures. On 22 April 2020, the board of directors resolved on the directed share issue authorised by the AGM held on 25 April 2019. In accordance with issue resolution and investment commitment, the subscription price shall be equal to the volume-weighted average price during the period 1–12 June 2020, however at maximum a of SEK 0.75. The board of directors determined the subscription price for the private placement to SEK 0.75 per share.

Abliva AB (publ) is a leader in mitochondrial medicine. The company’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. Abliva is listed on Nasdaq Stockholm.

Cirio advised Abliva with a team headed by Annika Andersson (Capital Markets and Public M&A), together with Oscar Lunde and Jesper M. Johansson (Capital Markets and Public M&A).

For more information, please contact: